Immunogenicity Data Drove Monkeypox Dose-Sparring Decision…It Also Drove Initial Approval

Comfort with the initial approval based on inferred effectiveness may have made the current EUA process more palatable to US FDA officials but means there is a bigger gap in what’s known about the vaccine’s effectiveness overall.

white house monkeypox press briefing Aug. 9, 2022
Biden administration officials discuss Jynneos EUA or dose-sparing vaccine strategy 9 August. • Source: White House Press Briefing

 The US Food and Drug Administration relied on a 2015 immunogenicity study to grant Bavarian Nordic A/S’ monkeypox vaccine Jynneos an emergency use authorization for administration by intradermal injection, a strategy that will increase the total number of doses available by up to five fold. (Also see "Monkeypox Vaccine: US FDA Eyes Dose-Sparing Strategy For Jynneos" - Pink Sheet, 4 August, 2022.)

One reason the agency may have been comfortable using immunogenicity data to grant the EUA for adults at high-risk of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet